MIRACLE Medical Technology Act of 2025
Summary
What This Bill Does
The MIRACLE Medical Technology Act of 2025 directs the Secretary of Health and Human Services, in consultation with the Secretary of Commerce, CMS technology leadership, and FDA, to run a program facilitating United States-Israel collaboration on the development and delivery of health care products and services. The program covers joint research projects, medical devices, pharmaceuticals, biological products, genomics, digital health, health systems management, early-stage clinical trials, biological product manufacturing, health-data sharing with the Israeli Ministry of Health, startup collaboration, technology acceptance, technology transfer, joint ventures, innovation hubs, cybersecurity standards, patient privacy, intellectual property protection, regulatory harmonization, biological product data protection, medical device commercialization, possible mutual recognition for pharmaceutical good manufacturing practices, confidentiality commitments between FDA and Israeli regulators, Project Orbis oncology submissions, clinical-care best practices, telemedicine, interoperability, disease prevention, vaccine development, epidemiological data sharing, joint manufacturing facilities in the United States, healthier nutrition sources, workforce training, exchange programs, supply-chain resilience, and public-private partnerships. HHS may establish a joint United States-Israel Health Care Collaboration Center in the United States, must begin implementation within six months, and receives an authorization of $8 million per year for fiscal years 2026 through 2030.
Who Benefits and How
U.S. medical device firms, pharmaceutical companies, biotechnology companies, digital health startups, universities, national laboratories, Israeli health care companies, and research institutions benefit from coordinated research, technology-transfer, regulatory, manufacturing, and commercialization pathways. Patients may benefit indirectly if collaboration accelerates treatments, diagnostics, biological products, telemedicine, vaccines, and oncology product review. U.S. manufacturing and supply-chain actors may benefit from joint biological product manufacturing and resilience planning.
Who Bears the Burden and How
HHS, Commerce, CMS, FDA, and other federal officials must coordinate the program, consult with Israeli counterparts, address privacy and cybersecurity standards, work on regulatory harmonization, support health-data sharing frameworks, begin implementation within six months, and potentially operate a collaboration center. Federal taxpayers bear the $8 million annual authorization for fiscal years 2026 through 2030. Participating companies and institutions may need to comply with data-sharing, intellectual-property, privacy, cybersecurity, regulatory, and confidentiality requirements.
Key Provisions
- Directs HHS to coordinate United States-Israel collaboration on health care products and services with Commerce, CMS technology leadership, and FDA consultation.
- Supports joint research, medical devices, pharmaceuticals, biological products, genomics, digital health, early-stage trials, technology transfer, and innovation hubs.
- Encourages health-data sharing frameworks, cybersecurity standards, patient privacy, intellectual property protection, regulatory harmonization, FDA-Israel confidentiality commitments, and Project Orbis collaboration.
- Authorizes a joint United States-Israel Health Care Collaboration Center in the United States and requires implementation within six months.
- Authorizes $8 million for each fiscal year from 2026 through 2030.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
Creates a United States-Israel health care collaboration program at HHS to coordinate medical technology, pharmaceuticals, digital health, biological products, data-sharing, manufacturing, and commercialization efforts.
Key Policy Areas
Healthcare, Biotech, Foreign Affairs, Technology
Primary Purpose
Creates a United States-Israel health care collaboration program at HHS to coordinate medical technology, pharmaceuticals, digital health, biological products, data-sharing, manufacturing, and commercialization efforts.
Policy Domains
Substantive provisions
Identified Gains
- Medical device companies
- Biotechnology companies
- Patients
Identified Costs
- Department of Health and Human Services
- Food and Drug Administration
- Federal taxpayers
Sponsors
Legislative Progress
In CommitteeMr. Buchanan (for himself, Mr. Soto, and Mrs. Miller-Meeks) introduced …
Referred to the House Committee on Energy and Commerce.
Introduced in House
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Department of Health and Human Services, Food and Drug Administration
Medical device companies, Patients using new medical technologies
Biotechnology companies, Pharmaceutical companies
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "Secretary"
- → Secretary of Health and Human Services
- "Commissioner"
- → Commissioner of Food and Drugs
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology